NOXXON Pharma N.V. announced positive top-line results from six months therapy of all patients in the NOX-A12 GLORIA Phase 1/2 dose-escalation study in ten brain cancer (glioblastoma) patients. GLORIA (NCT04121455) is NOXXON's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line glioblastoma patients with unmethylated MGMT promoter (resistant to standard chemotherapy). Three patients had been recruited in the 200 mg/week cohort, three patients in the 400 mg/week cohort and four patients in the 600 mg/week cohort, one of which dropped out and was replaced in September 2021.

The safety data seen at the dose level was consistent with what is to be expected in patients with glioblastoma receiving radiotherapy and similar to that seen in the lower dose cohorts. The percentage of patients who have achieved a best response of tumor size reduction under NOX-A12 treatment increased vs. the 89% disclosed in the previous interim data analysis presented at the Annual Meeting of the Society of Neuro-Oncology in November 2021.

Furthermore, the percentage of patients who have achieved more than 50% tumor size reduction under NOX-A12 treatment increased considerably over the 22.2% disclosed in the previous interim data analysis. Multiple patients in the high-dose cohort achieved >50% tumor size reductions, which is a multi-fold increase over the 7.7% achieved by the matched imaging reference cohort disclosed in November 2021.